Together, we can give all children with cancer a brighter future. Become a Friend of Rosie and help us.
Dr Mark Gaze is the Chair of the Friends of Rosie SAB. He has been a consultant clinical oncologist at University College London Hospitals and Great Ormond Street Hospital for Children since 1993. His areas of expertise include the management of cancer in children and young people with radiotherapy, and the use of radionuclide therapy in adults and children. Mark is committed to improving standards of care and has contributed to national guidance on good practice in Paediatric Radiotherapy and Molecular Radiotherapy.
Dr Sally George is a Paediatric Oncologist and a CRUK Clinician Scientist with an interest in paediatric solid tumours, specifically the common, poor outcome childhood tumour, neuroblastoma. In 2021, Dr George was awarded a CRUK Clinician Scientist Fellowship. Her laboratory-based research is focused on gaining a better understanding of how key changes during foetal development result in neuroblastoma in children – and using this knowledge to identify new treatments for children who are not cured by currently available therapies.
Dr Gray was appointed as a consultant in Paediatric Oncology at University Hospital Southampton NHS Foundation Trust in 2010. She is also an Associate Professor at the University of Southampton in the Centre for Cancer Immunology. Dr Gray looks after children with all types of malignancy but has a specific clinical and research interest in neuroblastoma and cancer immunotherapy. She leads several national and international neuroblastoma clinical trials and also oversees a laboratory research group focused on novel immunotherapies for children’s cancers.
Dr Kyle Matchett is a Lecturer in Molecular Immunology and Principal Investigator (PI) at the School of Medicine, Ulster University. In 2015, Dr Matchett was appointed as a Leukaemia and Leukaemia NI Postdoctoral Research Fellow following an increasing interest in haematology. His research focused on developing novel therapeutics for paediatric and adult acute myeloid leukaemia. This work has been recognised both nationally and internationally with a number of grants, invited talks and awards.
Dr Gail Horan is a Consultant Clinical Oncologist at Addenbrooke’s Hospital in Cambridge and Queen Elizabeth Hospital in King’s Lynn (from 2007). She is the Radiotherapy Lead for Sarcoma and Paediatrics at Addenbrooke’s and for Uro-oncology at Queen Elizabeth Hospital. Her main clinical interests are in all aspects of urology oncology, rarer tumours (sarcoma, myeloma) and total body irradiation. She is the Principal Investigator (PI) for several clinical trials, especially involving advanced radiotherapy techniques.
Dr Helen Bryant is Senior Lecturer and Head of The DNA replication and repair group at the University of Sheffield. Dr Bryant has worked in genome biology for 20 years. Dr Bryant’s area of specialism is understanding the control of the fidelity of DNA replication in normal cells and why defects in the proteins involved are associated with cancer. Her aim is to pinpoint differences between dividing tumour cells and dividing normal cells and determine which are important in cancer development. This has enabled the development of drugs which can specifically kill the tumour cells rather than just all dividing cells, also known as personalized therapy.
Katrina has specialised in the field of occupational personal injury for over 35 years and has worked exclusively for the victims of asbestos related diseases for the last 20 years. Katrina is an APIL Accredited Occupational Disease and Asbestos Disease Specialist and Senior Litigator and has Law Society Personal Injury Accreditation.
Carla has over 20 years’ experience specialising in strategic communications, engagement and marketing across the public and private sector, including the BBC, Manchester Metropolitan University and Muse Developments. She is currently Executive Director of Corporate Affairs and Marketing for The Growth Company, an award-winning social enterprise that enables growth, creates jobs and improves lives.
